ecancer

The immune microenvironment as an anti-cancer therapeutic strategy

Dr Lisa Coussens - Oregon Science & Health University, USA

12 Nov 2013

European Cancer Congress 2013 - News Roundup

Prof Gordon Mcvie - ecancer Managing Editor and the European Institute of Oncology

22 Oct 2013

Survival analysis of a follow-up phase III study of ipilimumab and dacarbazine in metastatic melanoma

Dr Michele Maio - University Hospital of Siena, Siena, Italy

4 Oct 2013

Opportunity for mobile treatment setting for lymphoedema patients

Rachel Iredale - Tenovus, Cardiff, Wales, UK

3 Oct 2013

Analysis of progression free survival versus overall survival in melanoma

Dr Keith Flaherty - Dana-Farber Cancer Institute, Boston, USA

3 Oct 2013

New antibody drug, MPDL3280A, in non-small cell lung cancer

Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France

3 Oct 2013

Meta-analysis of ipilimumab in metastatic or locally advanced, unresectable melanoma

Prof Dirk Schadendorf - Universitätsklinikum Essen, Essen, Germany

3 Oct 2013

Androgen blockade and ipilimumab against castration resistant prostate cancer

Dr Karim Fizazi - Institute Gustave Roussy, Paris, France

3 Oct 2013

ecancerNews Highlights from September 2013

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

24 Sep 2013

Developments with PD1 and immunotherapy in melanoma

Prof Lex Eggermont – Institut Gustave Roussy, Villejuif, France

19 Jul 2013

Establishing immunotherapy as a standard in cancer treatment

Prof Drew Pardoll – Johns Hopkins University School of Medicine, Baltimore, USA

18 Jul 2013

ECC 2013 Preview: Scientific programme highlights

Prof Vincenzo Valentini and Ian Banks

11 Jul 2013

More from ecancer